Precision Optics Corp Inc/Mass (POCI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$4.95+2.27%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · POCI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics.
Stated in 1 of 1 supplied quarters. Management reported: “Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics.” “For more information, please visit www.poci.com.” Revenue was $8.774 million in 2026-Q4.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics.”
Non-GAAP Financial Measures Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Uni…
Stated in 1 of 1 supplied quarters. Management reported: “Non-GAAP Financial Measures Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”).” “The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization).”
“Non-GAAP Financial Measures Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Uni…”
In addition to these items, Adjusted EBITDA excludes from Net Income (Loss) the effect of stock-based compensation, interest expense and interest income, depreciation and amortization and income taxe…
Stated in 1 of 1 supplied quarters. Management reported: “In addition to these items, Adjusted EBITDA excludes from Net Income (Loss) the effect of stock-based compensation, interest expense and interest income, depreciation and amortization and income taxes.” “This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company.” Gross profit was $2.224 million in 2026-Q4.
“In addition to these items, Adjusted EBITDA excludes from Net Income (Loss) the effect of stock-based compensation, interest expense and interest income, depreciation and amortization and income taxe…”
Focus on strategic initiatives to drive revenue growth and improve financial performance.
Enhance profitability by increasing gross margin through production efficiencies and higher-value product mix.
Over the trailing year it converted 0.63x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.